NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) shares were down more than 6% at last check Wednesday.
在周三的最后一次检查中，NeuroBo制药公司（纳斯达克股票代码：NRBO）股价下跌了6％以上。
The Boston-based company announced preclinical data for its novel "G-Protein-Coupled Receptor 119 (GPR119) agonist," known as DA-1241.
这家总部位于波士顿的公司公布了其名为 DA-1241 的新型 “G蛋白偶联受体119（GPR119）激动剂” 的临床前数据。
The data from a study on mice suggests that DA-1241 — combined with Novo Nordisk A/S's (NYSE:NVO) semaglutide (Wegovy) — improves liver fibrosis. It also demonstrates additive hepatoprotective effects compared to either treatment alone.
一项小鼠研究的数据表明，DA-1241 ——与诺和诺德A/S（纽约证券交易所代码：NVO）的索玛鲁肽（Wegovy）联合使用——可以改善肝纤维化。与单独使用任何一种治疗相比，它还显示出额外的保肝作用。
DA-1241 did not influence liver weight, the company said.
该公司表示，DA-1241 没有影响肝脏重量。
In contrast, semaglutide reduced body weight by approximately 25% and improved hepatomegaly in GAN DIO-MASH mice with or without combination treatment.
相比之下，无论是否进行联合治疗，索玛鲁肽使体重降低了约25％，并改善了GAN DIO-MASH小鼠的肝肿大。
There was no additional weight loss in the combination group compared to semaglutide alone.
与单独使用索玛鲁肽相比，组合组没有额外的体重减轻。
- DA-1241 and semaglutide monotherapy each improved NAS (≥2-point) in 21% of mice
- Combination treatment led to marked improvements (≥2-point in 80% of mice and ≥1-point in all mice), driven by reduction in steatosis and lobular inflammation scores.
- Combination therapy synergistically promoted quantitative histology for steatosis compared to monotherapies.
- Treatments did not significantly influence quantitative markers of fibrosis (PSR, Col1a1)
- DA-1241 and semaglutide in monotherapy lowered α-SMA levels with further improvement in combination treatment, suggesting additive inhibitory effects on fibrogenesis.
- At the end of treatment, semaglutide reduced body weight by approximately 17% (p < 0.05 vs. vehicle control), while DA-1241 (-2.8%) showed little effect.
- There was no additional weight loss in the combination group (-19%, p < 0.05) compared to semaglutide alone.
- Collagen fiber deposition was prominent in mice treated with vehicle compared to the normal control group.
- DA-1241 和索玛鲁肽单一疗法分别改善了 21% 小鼠的 NAS（≥2 点）
- 在脂肪变性和小叶炎评分下降的推动下，联合治疗带来了显著改善（80% 的小鼠≥2分，所有小鼠≥1分）。
- 与单一疗法相比，联合疗法协同促进了脂肪变的定量组织学。
- 治疗没有显著影响纤维化的定量标志物（PSR、Col1a1）
- 单一疗法中的 DA-1241 和索玛鲁肽降低了 α-SMA 水平，联合治疗进一步改善，这表明对纤维发生有额外的抑制作用。
- 在治疗结束时，索玛鲁肽使体重减轻了约17％（与车辆控制相比，p
- 与单独使用索玛鲁肽相比，该组合组没有额外的体重减轻（-19％，p
- 与正常对照组相比，接受载体治疗的小鼠的胶原纤维沉积非常明显。
DA-1241 or semaglutide alone lowered collagen-positive area compared to the vehicle-treated group (17.8%, 17.1% vs. 25.8%, p < 0.05). Their combination therapy elicited a further reduction to 6.05% (p < 0.05) compared with each treatment alone.
与车辆治疗组相比，单独使用 DA-1241 或索玛鲁肽可降低胶原蛋白阳性面积（17.8%，17.1% 对 25.8%，p
Price Action: NRBO shares are down 6.11% at $4.30 at last check Wednesday.
价格走势：在周三的最后一次检查中，NRBO股价下跌6.11％，至4.30美元。
Now Read: EXCLUSIVE – Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
立即阅读：独家——Roundhill Investments推出减肥ETF，用于投资Ozempic等重磅药物
Image: Shutterstock
图片：Shutterstock
译文内容由第三方软件翻译。